Investment Rating - The report maintains a "Buy" rating for the company, Sihuan Pharmaceutical (02096), with a target price of HKD 14.3, and continues to recommend it as a key focus in the industry [1]. Core Insights - The report has raised the profit forecast for the company for the years 2025-2027 by 6-11% and is optimistic about the potential for more overseas transactions in the short term, particularly focusing on targets such as CDH6 and CDH17, which have recently garnered significant attention [1]. - At the ASCO 2025 conference, the company's oncology pipeline showcased 18 research studies. Key studies to watch include: 1. The final analysis of overall survival (OS) in a Phase III study of Suviscita monoclonal antibody for platinum-resistant ovarian cancer, with median OS of 15.3 months for the treatment group compared to 14 months for the control group, with approval expected within the year [1]. 2. The results of an Ib phase study on SIM0270 combined with Palbociclib for second-line or higher ER+/HER2- breast cancer, showing an overall response rate (ORR) of 41.5% and clinical benefit rate (CBR) of 82.5%, with rates of 87.5% and 100% respectively in baseline ESR1 mutation patients. The company is currently conducting a Phase III study to evaluate the efficacy of SIM0270 combined with Everolimus in CDK4/6 inhibitor-treated ER+/HER2- breast cancer [1].

Investment Rating - The report maintains a "Buy" rating for the company Gu Ming (01364) [1] Core Insights - Gu Ming has achieved a same-store sales growth of approximately 10% this year, with store opening plans reaching 1,500 to 2,000, exceeding previous estimates [1] - UBS has raised the target price for Gu Ming from HKD 19.28 to HKD 31.15, corresponding to forecasted P/E ratios of 34x and 27x for 2025 and 2026 respectively [1] - The current valuation of Gu Ming is considered attractive at 1.3x dynamic P/E compared to the industry average of 1.9x [1] - The management has reiterated a long-term goal of reaching 30,000 stores by 2030, supporting an estimated annual store growth of about 20% [1] Financial Projections - UBS has increased the earnings per share forecast for Gu Ming for 2025 to 2027 by 6% to 11%, driven by a revenue forecast increase of 6% to 12%, reaching RMB 11.5 billion, RMB 14.1 billion, and RMB 17.2 billion respectively [2] - Same-store sales are expected to grow by 6% in 2025, supported by the introduction of coffee beverages [2]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 188.00 [9][10] Core Insights - The company has accelerated its product launch pace since March, introducing new products and IPs that are expected to contribute positively to growth in 2025 [2][4] - The establishment of the "Blokus System" creates competitive barriers through a standardized building block system, extensive patent layout, and a large, continuously expanding high-quality IP matrix [2][4] - The company aims for growth through a comprehensive approach targeting all demographics, price points, and global markets, indicating a clear growth trajectory [2][4] Summary by Sections Product Development and Market Expansion - The company has launched several new products in its main product line since March, including various iterations of popular IPs like Kamen Rider and Transformers [4] - The introduction of the Starry Edition series at a price point of HKD 9.9 has shown strong sales performance, expected to contribute significantly to 2025's revenue [4] - New products targeting adult fans and female demographics have also been introduced, indicating potential for market expansion [4] International Sales Growth - The company reported a 518% year-on-year increase in overseas sales revenue for 2024, reaching RMB 64 million, with significant contributions from Asia (excluding China) and North America [5] - Participation in international toy exhibitions has helped the company connect with global fans, and popular IPs have received licensing in multiple regions [5] Financial Projections and Valuation - The report maintains profit forecasts for 2025-2027, estimating adjusted net profits of RMB 11.81 billion, RMB 18.14 billion, and RMB 25.82 billion respectively [6] - The target price is based on a 36x PE ratio for 2025, reflecting the company's strong competitive position and growth potential [6][10] - Revenue projections show significant growth, with expected revenues of RMB 4.5 billion in 2025, up from RMB 2.24 billion in 2024 [8][19]

Investment Rating - The report maintains a "Strong Buy" investment rating for the company [2][5]. Core Views - The new game "Ethereal Reboot Day" has launched its international version on June 5, and the overall performance of older games remains stable. The company is expected to compensate for the natural decline in revenue from older games with new game launches, leading to a high degree of certainty in overall growth this year [1][5]. - The company has a robust pipeline of self-developed games, with significant contributions expected from titles like "Let's Go Muffin" and "Heart Town" in 2025, alongside several upcoming releases [5][6]. - The TapTap platform continues to expand, with a record high of 44 million monthly active users (MAU) in 2024, and revenue growth to 1.578 billion yuan. The platform's unique "no cooperation & zero revenue sharing" principle has attracted many developers [5][6]. - Financial projections indicate that the company's revenue is expected to reach 5.393 billion yuan in 2025, with a net profit of 1.027 billion yuan, reflecting a 27% year-on-year growth [6][8]. Summary by Sections Financial Data and Valuation - Total revenue for 2023 is projected at 3.389 billion yuan, with a significant increase to 5.012 billion yuan in 2024, and further growth to 5.393 billion yuan in 2025, representing a year-on-year growth of 48% and 8% respectively [6][8]. - The company is expected to achieve a net profit of 1.027 billion yuan in 2025, with a corresponding PE ratio of 17.2x [6][8]. - The gross margin is projected to improve from 61.0% in 2023 to 71.5% in 2025, indicating enhanced profitability [8]. Key Financial Ratios - The company's return on equity (ROE) is expected to be 30.7% in 2025, down from 32.3% in 2024, but still reflecting strong profitability [8]. - The debt-to-asset ratio is projected to decrease from 30.8% in 2024 to 25.3% in 2025, indicating improved financial stability [8]. - The current ratio is expected to rise from 3.1 in 2024 to 3.8 in 2025, suggesting better liquidity [8].

Investment Rating - The report initiates coverage with a "Neutral" rating for the company, projecting a target price of 36.48 HKD based on cautious valuation methods [4][11]. Core Insights - The company is undergoing an AI strategic transformation, shifting focus from digital tax solutions to "Data Intelligence" applications, leveraging its data assets and AI capabilities [4][26]. - Revenue projections for 2025-2027 are estimated at 0.85 billion, 1.02 billion, and 1.18 billion RMB, with year-on-year growth rates of 29.18%, 19.16%, and 16.65% respectively [7][37]. - The net profit attributable to shareholders is expected to improve significantly, moving from a loss of 7.87 million RMB in 2025 to a profit of 107 million RMB by 2027, reflecting growth rates of 98.43%, 759.27%, and 105.56% [7][37]. Financial Summary - The company reported a total revenue of 6.59 billion RMB in 2024, a decrease of 8% year-on-year, with specific segments showing varied performance [23]. - The gross margin for 2024 was 40%, with cloud tax solutions achieving a gross margin of 52.2% and local deployment solutions at 23.6% [24]. - Significant cost control measures have been implemented, resulting in a reduction of sales and administrative expense ratios [25]. Business Overview - Founded in 2015, the company specializes in data-driven AI solutions, focusing on digital tax and data analytics services [15][34]. - The Baiwang Cloud Platform integrates various technologies, including digital certificates, AI, and blockchain, to provide comprehensive digital business solutions [16][34]. - The company serves a diverse client base, with 2,664 clients for local tax solutions and 28.4 million non-paying users for cloud solutions [22][37]. AI Strategic Transformation - The appointment of a new CEO, a former leader in AI, signals a commitment to enhancing AI capabilities within the company's operations [26]. - The strategic focus includes developing AI-driven solutions for digital tax and financial risk management, aiming to unlock the value of extensive transaction data [26][27]. Market Expansion - The company is actively entering the data element market, collaborating with national entities to establish a data resource registration system [27]. - This initiative aims to facilitate the circulation of data assets and enhance the overall data resource ecosystem in China [27].

Investment Rating - The report maintains an "Add" rating for the company [5] Core Views - The strategic cooperation agreement between the company and Yaoshi Bang aims to explore the application of intelligent robots in the pharmaceutical industry, focusing on areas such as research, warehousing, distribution, retail, and medication services [2] - The company has demonstrated strong generalization capabilities in its robots, which can adapt to various tasks in the pharmaceutical environment, including sorting and transporting medications [3] - The increasing deployment of humanoid robots in various industries is expected to accelerate their mass production and commercialization [4] Financial Forecasts - The company’s revenue projections for 2025, 2026, and 2027 are estimated at 4.96 billion, 6.73 billion, and 8.97 billion respectively, with corresponding price-to-sales ratios of 46, 34, and 25 [5] - The net profit for 2025 is projected to be a loss of 43.49 million, with a turnaround expected in 2026, achieving a profit of 1.15 million, and further increasing to 34.54 million in 2027 [5] - The earnings per share (EPS) is expected to improve from a loss of 0.11 in 2025 to a profit of 0.09 in 2027 [5]

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 84.00, indicating a potential upside of 16.2% from the current price of HKD 72.30 [4][14]. Core Insights - The early data for IBI363 in lung cancer is encouraging, revealing a significant market opportunity. The target price has been raised due to the inclusion of IBI363 in the valuation model, with an estimated peak sales potential of approximately USD 1.5 billion by 2028 [2][7]. - The company plans to initiate a Phase III registration study for IBI363 in squamous NSCLC patients who have failed prior PD-(L)1 therapy, having received breakthrough therapy designation from CDE [7][10]. Financial Overview - Revenue projections show a strong growth trajectory, with expected revenues of RMB 6,206 million in 2023, increasing to RMB 17,071 million by 2027, representing a compound annual growth rate (CAGR) of 36.2% from 2023 to 2024 and 20.0% from 2026 to 2027 [3][15]. - The net profit is projected to turn positive in 2025, with an estimated net profit of RMB 751 million, growing to RMB 3,242 million by 2027 [3][15]. - The earnings per share (EPS) is expected to improve significantly, moving from a loss of RMB 0.66 in 2023 to a profit of RMB 1.97 by 2027 [3][15]. Clinical Data Highlights - IBI363 demonstrated an overall response rate (ORR) of 26-37% in squamous NSCLC patients, with a median progression-free survival (PFS) of 5.5-9.3 months and a median overall survival (OS) exceeding 15.3 months [7][8]. - In the non-squamous NSCLC cohort, the ORR was 24% with a median PFS of 5.6 months, indicating the drug's potential effectiveness in a challenging treatment landscape [7][9]. Market Potential - The report highlights a significant unmet need in the second-line treatment for I/O resistant NSCLC patients, with current therapies showing an ORR of less than 20% and median PFS/OS of less than 4 months/12 months [7][10]. - The global sales for PD-(L)1 drugs are projected to exceed USD 40 billion in 2024, underscoring the substantial market opportunity for effective therapies like IBI363 [7].

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 84.00, indicating a potential upside of 16.2% from the current closing price of HKD 72.30 [4][14]. Core Insights - The early clinical data for IBI363 in lung cancer is encouraging, revealing a significant market opportunity. The target market for IBI363 is characterized as a "blue ocean" due to limited existing treatment options for first-line I/O resistant NSCLC patients [2][7]. - The report projects that IBI363 could achieve peak sales of approximately USD 1.5 billion by 2028, based on a conservative estimate of capturing around 10% of the post-PD-(L)1 treatment market with a 40% success rate [7][10]. - The financial forecasts show substantial revenue growth, with expected revenues increasing from RMB 6,206 million in 2023 to RMB 17,071 million by 2027, reflecting a compound annual growth rate (CAGR) of 36.2% from 2023 to 2024 and 20.0% from 2026 to 2027 [3][15]. Financial Overview - Revenue projections for the company are as follows: RMB 6,206 million in 2023, RMB 9,422 million in 2024, RMB 11,782 million in 2025, RMB 14,231 million in 2026, and RMB 17,071 million in 2027, with year-on-year growth rates of 36.2%, 51.8%, 25.1%, 20.8%, and 20.0% respectively [3][15]. - The net profit is expected to turn positive in 2025, reaching RMB 751 million, and further increasing to RMB 3,242 million by 2027 [3][15]. - The earnings per share (EPS) is projected to improve from a loss of RMB 0.66 in 2023 to a profit of RMB 1.97 by 2027 [3][15]. Clinical Data Highlights - IBI363 demonstrated an overall response rate (ORR) of 26-37% in squamous NSCLC patients, with a median progression-free survival (PFS) of 5.5-9.3 months and a median overall survival (OS) exceeding 15.3 months [7][8]. - In the EGFR wild-type non-squamous NSCLC cohort, the ORR was 24% with a median PFS of 5.6 months [7][9]. - The safety profile of IBI363 is reported to be manageable, with the most common grade 3 adverse events being joint pain and rash [7].

证券研究报告 布鲁可 (325 HK) 2025 年中期策略会速递— 稳步推新，迈向破圈，成长势能强劲 | 华泰研究 | | | 更新报告 | | --- | --- | --- | --- | | 2025 年 | 6 月 | 06 日│中国香港 | 消费轻工 | 6 月 4-5 日布鲁可出席我们举办的 2025 年中期策略会，就市场关注的发展 策略等核心问题进行分享，我们总结要点：1）看趋势，3 月以来公司推新 节奏加快，新产品及新 IP 陆续上新，我们认为有望贡献增长亮点，看好 25 年全年经营势能向上；2）看壁垒，公司建立并深耕"布鲁可体系"，结合标 准化积木系统+广泛专利布局、庞大且持续拓展的高质量 IP 矩阵、高效上新 &好而不贵的产品体系建立竞争护城河；3）看远景，我们认为公司以全人 群+全价位+全球化为增长引擎，未来有望在客群端破圈、在价位端延展、 在海外市场加速布局，增长曲线清晰。我们看好公司作为优质 IP 商业化平 台的长期增长潜力及稀缺性，上调目标价至 188 港币，维持"买入"评级。 推新节奏加快，下沉市场表现亮眼，迈向客群破圈 3 月以来公司推新节奏明显加快：1）主力产品群星版中，3 ...

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 47.00 [5][8]. Core Insights - The company is focusing on high-quality growth through channel optimization and product offerings, with expectations for same-store sales to turn positive in May [1][2]. - The company is enhancing its overseas operations with localized strategies and optimizing direct store expenses, which is expected to drive revenue growth [3][4]. - Short-term profit fluctuations are anticipated due to the ramp-up phase of high-growth businesses, but improvements in operational models are expected to enhance profitability [4]. Summary by Sections Domestic Operations - The company is adjusting its product offerings to better match market demands, focusing on high-quality products in higher-tier markets and cost-effective options in lower-tier markets [2]. - The closure of underperforming stores and the opening of flagship "IP Land" stores are part of the strategy to drive growth, with expectations for same-store sales to stabilize [2]. Overseas Operations - The company aims to increase its store count by 500-600 locations this year, with improvements in same-store sales in North America due to cost optimization strategies [3]. - The establishment of a product development team in North America is expected to enhance operational efficiency and profitability [3]. Financial Projections - The adjusted net profit forecasts for 2025-2027 are RMB 29.9 billion, RMB 37.3 billion, and RMB 45.7 billion respectively, with a target price based on a PE ratio of 18x for 2025 [5][7]. - Revenue projections show a growth trajectory with expected revenues of RMB 20.7 billion in 2025, reflecting a year-on-year increase of 21.83% [7][19].